

To: [REDACTED] [REDACTED]@cbg-meb.nl; [REDACTED] [REDACTED]@ema.europa.eu
Cc: [REDACTED] [REDACTED]@ema.europa.eu; [REDACTED] [REDACTED]@cbg-meb.nl; [REDACTED] [REDACTED]@cbg-meb.nl; [REDACTED] [REDACTED]@cbg-meb.nl
From: [REDACTED]
Sent: Fri 3/27/2020 5:04:17 PM
Subject: RE: EU Executive Steering Group - list of essential medicines COVID-19 patients - The Netherlands
Received: Fri 3/27/2020 5:05:25 PM

Dear [REDACTED]

Thank you for the info below and please rest assured that we will draw up the list without releasing any MS-level information.

Wishing you a good weekend.

Best regards

[REDACTED]

Classified as confidential by the European Medicines Agency

-----Original Message-----

From: [REDACTED] <[REDACTED]@cbg-meb.nl>
Sent: 26 March 2020 17:46
To: [REDACTED] <[REDACTED]@ema.europa.eu>; [REDACTED] <[REDACTED]@ema.europa.eu>
Cc: [REDACTED] <[REDACTED]@ema.europa.eu>; [REDACTED] <[REDACTED]@cbg-meb.nl>; [REDACTED] <[REDACTED]@cbg-meb.nl>; [REDACTED] <[REDACTED]@cbg-meb.nl>
Subject: Re: EU Executive Steering Group - list of essential medicines COVID-19 patients - The Netherlands

Dear [REDACTED]

In addition to what we sent earlier today I would like to draw your attention to the following concerning possible shortages:

We continuously receive updates of a list from Hospital pharmacists in the Netherlands with notices from shortages of medicines relating to COVID-19. These notices however, do not directly imply that there is a shortage; there could still be stock in a different stage of the distribution line. Therefore, we rely more on the notices of the MAH's.

We do face a shortage of propofol, which could possibly be related to the problem that Medicines for Europe noted, regarding the logistics of narcotic products within Europe.

Regarding treatment options for COVID-19, the Dutch Journal of Medicine ('Nederlands Tijdschrift voor Geneeskunde', or NTvG) published the following on their website yesterday:
<https://www.ntvg.nl/artikelen/geneesmiddelen-bij-covid-19/volledig>

Only chloroquine and remdesivir are mentioned as (experimental) treatment options. Hydrochloroquine is also mentioned, but due to very limited availability, it is mentioned that this is no realistic option. Lopinavir/ritonavir has been deleted as treatment option.

Finally, we would like to ask EMA to make sure that when drawing up the list of essential medicines, our contribution cannot be traced back to country-level.

Thanks and kind regards,

[REDACTED]

Van: "[REDACTED]" <[REDACTED]@ema.europa.eu> <[REDACTED]@ema.europa.eu>>
Datum: donderdag 26 maart 2020 om 11:59:45
Aan: "[REDACTED]" <[REDACTED]@cbg-meb.nl> <[REDACTED]@cbg-meb.nl>>, "[REDACTED]" <[REDACTED]@ema.europa.eu> <[REDACTED]@ema.europa.eu>>
Cc: "[REDACTED]" <[REDACTED]@ema.europa.eu> <[REDACTED]@ema.europa.eu>>, "[REDACTED]" <[REDACTED]@cbg-meb.nl> <[REDACTED]@cbg-meb.nl>>, "[REDACTED]" <[REDACTED]@cbg-meb.nl> <[REDACTED]@cbg-meb.nl>>, "[REDACTED]" <[REDACTED]@cbg-meb.nl> <[REDACTED]@cbg-meb.nl>>
Onderwerp: RE: EU Executive Steering Group - list of essential medicines COVID-19 patients - The Netherlands

Dear [REDACTED]

Thank you very much.

Best regards

5.1.2e

Classified as confidential by the European Medicines Agency

From: 5.1.2e <5.1.2e@cbg-meb.nl>

Sent: 26 March 2020 11:55

To: 5.1.2e <5.1.2e@ema.europa.eu>; 5.1.2e <5.1.2e@ema.europa.eu>

Cc: 5.1.2e <5.1.2e@ema.europa.eu>; 5.1.2e <5.1.2e@cbg-meb.nl>; 5.1.2e <5.1.2e@cbg-meb.nl>; 5.1.2e <5.1.2e@cbg-meb.nl>

Subject: EU Executive Steering Group - list of essential medicines COVID-19 patients - The Netherlands

Importance: High

Dear 5.1.2e

In follow-up to today's EU Executive SG please find attached two files:

1. MEB-assessment of WHO list of essential medicines COVID-19 (resending file from 17 March 2020);
2. List of essential medicines IC COVID-19 - as retrieved from Dutch hospitals - 23 March 2020.

Kind regards,

5.1.2e

5.1.2e

5.1.2e

Tel.: +31 6 5.1.2e

5.1.2e

@01D60365.D94227E0]<<https://english.cbg-meb.nl/>>

Van: 5.1.2e <5.1.2e@cbg-meb.nl> <5.1.2e@cbg-meb.nl>>

Verzonden: dinsdag 17 maart 2020 18:55

Aan: 5.1.2e <5.1.2e@ema.europa.eu> <5.1.2e@ema.europa.eu>; 5.1.2e <5.1.2e@cbg-meb.nl> <5.1.2e@cbg-meb.nl>>

CC: 5.1.2e <5.1.2e@ema.europa.eu> <5.1.2e@ema.europa.eu>; 5.1.2e <5.1.2e@cbg-meb.nl> <5.1.2e@cbg-meb.nl>>; 5.1.2e <5.1.2e@ema.europa.eu> <5.1.2e@ema.europa.eu>>

<5.1.2e@ema.europa.eu> <5.1.2e@ema.europa.eu>>

Onderwerp: RE: EU Executive Steering Group - list of medicines used for the treatment of COVID-19 patients

Dear 5.1.2e

First of all, please accept our apologies for our late response. Please find attached the list, in which we have indicated which medicines are being used in the Netherlands. Only for the last 3 medicines mentioned, an effect on COVID-19 could be expected.

Of the medicines mentioned in the categories Diabetes, Hypertension, HIV, TB, Malaria, Pregnancy/maternal, Heparine we only expect negligible effects on COVID-19.

Furthermore, regarding medicines not mentioned in the list:

- * Symptomatic treatment: especially paracetamol en possibly nose spray. We don't expect any NSAIDs anymore.
- * In intensive care, complete scala: inotropica (noradrenaline) and sedatives (midazolam, propofol).

Possibly also amoxicilline/clavulaanzuur, ceftraxon en piperacilline/tazobactam extra (in case of more patients in one unit)

Kind regards,

5.1.2e

5.1.2e

@01D60365.C56AF670]<<https://english.cbg-meb.nl/>>

Medicines Evaluation Board

5.1.2e

@cbg-meb.nl<

5.1.2e

@cbg-meb.nl>

+31 (0)88 5.1.2e | +31 (0) 6 5.1.2e
 +www.cbg-meb.nl<https://english.cbg-meb.nl/>
 Graadt van Roggenweg 500 | 3531 AH Utrecht The Netherlands

[LinkedInCBGgrey]<https://www.linkedin.com/company/college-ter-beoordeling-van-geneesmiddelen/> [TwitterCBGgrey]
 <https://twitter.com/MedicijnNL>

GOOD MEDICINES USED BETTER

Van: 5.1.2e [5.1.2e]@ema.europa.eu]
 Verzonden: dinsdag 17 maart 2020 15:22
 Aan: 5.1.2e
 CC: 5.1.2e; 5.1.2e; 5.1.2e; 5.1.2e
 Onderwerp: RE: EU Executive Steering Group - list of medicines used for the treatment of COVID-19 patients

Hi 5.1.2e

Thank you for informing us about the MEB participation to tomorrow meeting. Regarding the meeting documents, they will be shared shortly together with the dial in instructions.

We look forward to receiving your feedback on the list of priority medicines.

Many thanks

5.1.2e

Classified as confidential by the European Medicines Agency

From: 5.1.2e
 Sent: 17 March 2020 14:40
 To: 5.1.2e
 Cc: 5.1.2e; 5.1.2e; 5.1.2e
 Subject: RE: EU Executive Steering Group - list of medicines used for the treatment of COVID-19 patients

Hi 5.1.2e

thanks for these documents - we will look into them and try to provide feedback asap.

Two points for tomorrow's EU SG:

1. Participation MEB - in absence of 5.1.2e MEB will be represented by 5.1.2e - in cc to this message) and myself.

1. I have not yet seen meeting documents and dial-in details for tomorrow's meeting. Is this correct or have I overlooked them?

Thanks and kind regards,

5.1.2e

Van: 5.1.2e <5.1.2e@ema.europa.eu<5.1.2e@ema.europa.eu>>
 Verzonden: maandag 16 maart 2020 18:19
 Aan: 5.1.2e <5.1.2e@bvl.bund.de<5.1.2e@bvl.bund.de>>; 5.1.2e
 <5.1.2e@dkma.dk<5.1.2e@dkma.dk>>; 5.1.2e
 <5.1.2e@ema.europa.eu<5.1.2e@ema.europa.eu>>; 5.1.2e @bfarm.de'
 <5.1.2e@bfarm.de<5.1.2e@bfarm.de>>; 5.1.2e @ec.europa.eu' <5.1.2e
 5.1.2e @ec.europa.eu<5.1.2e@ec.europa.eu>>; 5.1.2e @ec.europa.eu'; 5.1.2e
 <5.1.2e@ema.europa.eu<5.1.2e@ema.europa.eu>>; 5.1.2e @aemps.es'
 <5.1.2e@aemps.es<5.1.2e@aemps.es>>; 5.1.2e <5.1.2e@cbg-meb.nl<5.1.2e@cbg-meb.nl>>;
 5.1.2e @ansm.sante.fr' <5.1.2e@ansm.sante.fr<5.1.2e@ansm.sante.fr>>;
 5.1.2e @anses.fr'; 5.1.2e <5.1.2e@ema.europa.eu<5.1.2e@ema.europa.eu>>;

5.1.2e <5.1.2e@ema.europa.eu>; 5.1.2e @ec.europa.eu'
 <5.1.2e@ec.europa.eu>; 5.1.2e @ravimiamet.ee'
 <5.1.2e@ravimiamet.ee>; 5.1.2e
 <5.1.2e@ema.europa.eu>; 5.1.2e @hpra.ie'
 <5.1.2e@hpra.ie>; 5.1.2e
 <5.1.2e@ema.europa.eu>
 CC: 5.1.2e <5.1.2e@cbg-meb.nl>; 5.1.2e @cbg-meb.nl>; 5.1.2e <5.1.2e@cbg-meb.nl>; 5.1.2e @dkma.dk<5.1.2e@dkma.dk>; 5.1.2e @bvl.bund.de<5.1.2e@bvl.bund.de>; 5.1.2e @bvl.bund.de<5.1.2e@bvl.bund.de>>

Onderwerp: EU Executive Steering Group - list of medicines used for the treatment of COVID-19 patients

Dear colleagues

The WHO developed a list of priority medicines in the context of the COVID-19 outbreak that are needed for primary care and basic hospital functioning. The WHO list includes a number of medicines which may be used in the management of COVID-19 patients (symptomatic or anti-viral) but the list is not exhaustive and does not cover new investigational medicines.

In preparation for the next meeting of the EU Executive Steering Group on Wednesday, we would like to receive feedback from Heads of Agencies on the following:

- * From the list of priority medicines developed by the WHO in the context of the COVID-19 outbreak (see attached), which medicines are not used in your country
- * Are there any medicines not in this list being used for the treatment of COVID-19 patients in your country

Many thanks

5.1.2e

Classified as confidential by the European Medicines Agency

This e-mail has been scanned for all known viruses by European Medicines Agency.

This inbound message has been checked for all known viruses by KPN's Secure Information Exchange service, powered by Symantec.cloud.

This outbound message has been checked for all known viruses by KPN's Secure Information Exchange service, powered by Symantec.cloud.

This e-mail has been scanned for all known viruses by European Medicines Agency.

This inbound message has been checked for all known viruses by KPN's Secure Information Exchange service, powered by Symantec.cloud.

This outbound message has been checked for all known viruses by KPN's Secure Information Exchange service, powered by Symantec.cloud.

This e-mail has been scanned for all known viruses by European Medicines Agency.

This inbound message has been checked for all known viruses by KPN's Secure Information Exchange service, powered by Symantec.cloud.

This outbound message has been checked for all known viruses by KPN's Secure Information Exchange service, powered by Symantec.cloud.

This e-mail has been scanned for all known viruses by European Medicines Agency.
